|
1
|
Barski A, Cuddapah S, Cui K, Roh TY,
Schones DE, Wang Z, Wei G, Chepelev I and Zhao K: High-resolution
profiling of histone methylations in the human genome. Cell.
129:823–837. 2007. View Article : Google Scholar
|
|
2
|
Mikkelsen TS, Ku M, Jaffe DB, Issac B,
Lieberman E, Giannoukos G, Alvarez P, Brockman W, Kim TK, Koche RP,
et al: Genome-wide maps of chromatin state in pluripotent and
lineage-committed cells. Nature. 448:553–560. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tsukada YI, Fang J, Erdjument-Bromage H,
Warren ME, Borchers CH, Tempst P and Zhang Y: Histone demethylation
by a family of JmjC domain-containing proteins. Nature.
439:811–816. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shukla A, Chaurasia P and Bhaumik SR:
Histone methylation and ubiquitination with their cross-talk and
roles in gene expression and stability. Cell Mol Life Sci.
66:1419–1433. 2009. View Article : Google Scholar
|
|
5
|
Jambhekar A, Dhall A and Shi Y: Roles and
regulation of histone methylation in animal development. Nat Rev
Mol Cell Biol. 20:625–641. 2019. View Article : Google Scholar
|
|
6
|
Plch J, Hrabeta J and Eckschlager T: KDM5
demethylases and their role in cancer cell chemoresistance. Int J
Cancer. 144:221–231. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ruthenburg AJ, Allis CD and Wysocka J:
Methylation of lysine 4 on histone H3: Intricacy of writing and
reading a single epigenetic mark. Mol Cell. 25:15–30. 2007.
View Article : Google Scholar
|
|
8
|
Arifuzzaman S, Khatun MR and Khatun R:
Emerging of lysine demethylases (KDMs): From pathophysiological
insights to novel therapeutic opportunities. Biomed Pharmacother.
129:1103922020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sterling J, Menezes SV, Abbassi RH and
Munoz L: Histone lysine demethylases and their functions in cancer.
Int J Cancer. 148:2375–2388. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang N, Ma T and Yu B: Targeting
epigenetic regulators to overcome drug resistance in cancers.
Signal Transduct Target Ther. 8:692023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu H, Xu L and Hu X: KDM5A regulates the
growth and gefitinib drug resistance against human lung
adenocarcinoma cells 3. Biotech. 12:972022.
|
|
12
|
Banelli B, Carra E, Barbieri F, Würth R,
Parodi F, Pattarozzi A, Carosio R, Forlani A, Allemanni G, Marubbi
D, et al: The histone demethylase KDM5A is a key factor for the
resistance to temozolomide in glioblastoma. Cell Cycle.
14:3418–3429. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Feng T, Wang Y, Lang Y and Zhang Y: KDM5A
promotes proliferation and EMT in ovarian cancer and closely
correlates with PTX resistance. Mol Med Rep. 16:3573–3580. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hou J, Wu J, Dombkowski A, Zhang K,
Holowatyj A, Boerner JL and Yang ZQ: Genomic amplification and a
role in drug-resistance for the KDM5A histone demethylase in breast
cancer. Am J Transl Res. 4:247–256. 2012.PubMed/NCBI
|
|
15
|
Roesch A, Vultur A, Bogeski I, Wang H,
Zimmermann KM, Speicher D, Körbel C, Laschke MW, Gimotty PA,
Philipp SE, et al: Overcoming intrinsic multidrug resistance in
melanoma by blocking the mitochondrial respiratory chain of
slow-cycling JARID1B high cells. Cancer Cell. 23:811–825. 2013.
View Article : Google Scholar
|
|
16
|
Xu W, Zhou B, Zhao X, Zhu L, Xu J, Jiang
Z, Chen D, Wei Q, Han M, Feng L, et al: KDM5B demethylates H3K4 to
recruit XRCC1 and promote chemoresistance. Int J Biol Sci.
14:1122–1132. 2018. View Article : Google Scholar
|
|
17
|
Liu J and Nie C: KDM5B regulates the
PTEN/PI3K/Akt pathway to increase sorafenib-resistance in
hepatocellular carcinoma. Anticancer Drugs. 33:840–849. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Belhajova M, Podhorska N, Vicha A and
Eckschlager T: KDM5B expression in cisplatin resistant
neuroblastoma cell lines. Oncol Lett. 24:3652022. View Article : Google Scholar
|
|
19
|
Kuo YT, Liu YL, Adebayo BO, Shih PH, Lee
WH, Wang LS, Liao YF, Hsu WM, Yeh CT and Lin CM: JARID1B expression
plays a critical role in chemoresistance and stem cell-like
phenotype of neuroblastoma cells. PLoS One. 10:e01253432015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li L, Shou H, Wang Q and Liu S:
Investigation of the potential theranostic role of KDM5B/miR-29c
signaling axis in paclitaxel resistant endometrial carcinoma. Gene.
694:76–82. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang L, Mao Y, Du G, He C and Han S:
Overexpression of JARID1B is associated with poor prognosis and
chemotherapy resistance in epithelial ovarian cancer. Tumor Biol.
36:2465–2472. 2015. View Article : Google Scholar
|
|
22
|
Lin H, Yang G, Yu J, Wang J, Li Q, Guo S
and Cao B: KDM5C inhibits multidrug resistance of colon cancer cell
line by down-regulating ABCC1. Biomed Pharmacother. 107:1205–1209.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hong Z, Wu G, Xiang ZD, Xu CD, Huang SS,
Li C, Shi L and Wu DL: KDM5C is transcriptionally regulated by BRD4
and promotes castration-resistance prostate cancer cell
proliferation by repressing PTEN. Biomed Pharmacother.
114:1087932019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Outchkourov NS, Muiño JM, Kaufmann K, van
IJcken WF, Groot Koerkamp MJ, van Leenen D, de Graaf P, Holstege
FC, Grosveld FG and Timmers HT: Balancing of histone H3K4
methylation states by the Kdm5c/SMCX histone demethylase modulates
promoter and enhancer function. Cell Rep. 3:1071–1079. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Agulnik AI, Longepied G, Ty MT and Bishop
CE: Mitchell M0020: Mouse H-Y encoding Smcy gene and its X
chromosomal homolog Smcx. Mamm Genome. 10:926–929. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Akimoto C, Kitagawa H, Matsumoto T and
Kato S: Spermatogenesis-specific association of SMCY and MSH5.
Genes Cells. 13:623–633. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Komura K, Jeong SH, Hinohara K, Qu F, Wang
X, Hiraki M, Azuma H, Lee GS, Kantoff PW and Sweeney CJ: Resistance
to docetaxel in prostate cancer is associated with androgen
receptor activation and loss of KDM5D expression. Proc Natl Acad
Sci USA. 113:6259–6264. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jangravi Z, Tabar MS, Mirzaei M,
Parsamatin P, Vakilian H, Alikhani M, Shabani M, Haynes PA,
Goodchild AK, Gourabi H, et al: Two splice variants of Y
chromosome-located lysine-specific Demethylase 5D have distinct
function in prostate cancer cell line (DU-145). J Proteome Res.
14:3492–3502. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li N, Dhar SS, Chen TY, Kan PY, Wei Y, Kim
JH, Chan CH, Lin HK, Hung MC and Lee MG: JARID1D is a suppressor
and prognostic marker of prostate cancer invasion and metastasis.
Cancer Res. 76:831–843. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Arseneault M, Monlong J, Vasudev NS,
Laskar RS, Safisamghabadi M, Harnden P, Egevad L, Nourbehesht N,
Panichnantakul P, Holcatova I, et al: Loss of chromosome Y leads to
down regulation of KDM5D and KDM6C epigenetic modifiers in clear
cell renal cell carcinoma. Sci Rep. 7:448762017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhu M, Zhang RN, Zhang H, Qu CB, Zhang XC,
Ren LX, Yang Z and Gu JF: PCGF6/MAX/KDM5D facilitates MAZ/CDK4 axis
expression and pRCC progression by hypomethylation of the DNA
promoter. Epigenetics Chromatin. 16:92023. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen TM, Huang CM, Setiawan SA, Hsieh MS,
Sheen CC and Yeh CT: KDM5D histone demethylase identifies
platinum-tolerant head and neck cancer cells vulnerable to mitotic
catastrophe. Int J Mol Sci. 24:53102023. View Article : Google Scholar
|
|
33
|
Dunford A, Weinstock DM, Savova V,
Schumacher SE, Cleary JP, Yoda A, Sullivan TJ, Hess JM, Gimelbrant
AA, Beroukhim R, et al: Tumor-suppressor genes that escape from
X-inactivation contribute to cancer sex bias. Nature Genet.
49:10–16. 2017. View Article : Google Scholar
|
|
34
|
Shen X, Hu K, Cheng G, Xu L, Chen Z, Du P
and Zhuang Z: KDM5D inhibit epithelial-mesenchymal transition of
gastric cancer through demethylation in the promoter of Cul4A in
male. J Cell Biochem. 120:12247–12258. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu M and Gao N: KDM5D inhibits the
transcriptional activation of FKBP4 by suppressing the expression
of E2F1 in colorectal cancer in males. Biochem Pharmacol.
194:1148142021. View Article : Google Scholar
|
|
36
|
Li S, Wu Z, Li Q, Liang Q, Zhou H, Shi Y,
Zhang R and Pan H: The prognostic value of AT-rich interaction
domain (ARID) family members in patients with hepatocellular
carcinoma. Evid Based Complement Alternat Med.
2022:11503902022.PubMed/NCBI
|
|
37
|
Duan Y, Du Y, Gu Z, Zheng X and Wang C:
Expression, prognostic value, and functional mechanism of the KDM5
family in pancreatic cancer. Front Cell Dev Biol. 10:8873852022.
View Article : Google Scholar
|
|
38
|
Abdel-Hafiz HA, Schafer JM, Chen X, Xiao
T, Gauntner TD, Li Z and Theodorescu D: Y chromosome loss in cancer
drives growth by evasion of adaptive immunity. Nature. 619:624–631.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li J, Lan Z, Liao W, Horner JW, Xu X, Liu
J, Yoshihama Y, Jiang S, Shim HS, Slotnik M, et al: Histone
demethylase KDM5D upregulation drives sex differences in colon
cancer. Nature 619: 632–639, 2023. Hannah J and Zhou P: Distinct
and overlapping functions of the cullin E3 ligase scaffolding
proteins CUL4A and CUL4B. Gene. 573:33–45. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jin J, Arias EE, Chen J, Harper JW and
Walter JC: A family of diverse Cul4-Ddb1-interacting proteins
includes Cdt2, which is required for S phase destruction of the
replication factor Cdt1. Mol Cell. 23:709–721. 2006. View Article : Google Scholar
|
|
41
|
Yasui K, Arii S, Zhao C, Imoto I, Ueda M,
Nagai H, Emi M and Inazawa J: TFDP1, CUL4A, and CDC16 identified as
targets for amplification at 13q34 in hepatocellular carcinomas.
Hepatology. 35:1476–1484. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Jia L, Yan F, Cao W, Chen Z, Zheng H, Li
H, Pan Y, Narula N, Ren X, Li H and Zhou P: Dysregulation of CUL4A
and CUL4B Ubiquitin ligases in lung cancer. J Biol Chem.
292:2966–2978. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hannah J and Zhou PB: The CUL4A ubiquitin
ligase is a potential therapeutic target in skin cancer and other
malignancies. Chin J Cancer. 32:478–482. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chen LC, Manjeshwar S, Lu Y, Moore D,
Ljung BM, Kuo WL, Dairkee SH, Wernick M, Collins C and Smith HS:
The human homologue for the Caenorhabditis elegans cul-4 gene is
amplified and overexpressed in primary breast cancers. Cancer Res.
58:3677–3683. 1998.PubMed/NCBI
|
|
45
|
Hung MS, Mao JH, Xu Z, Yang CT, Yu JS,
Harvard C, Lin YC, Bravo DT, Jablons DM and You L: Cul4A is an
oncogene in malignant pleural mesothelioma. J Cell Mol Med.
15:350–358. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ren S, Xu C, Cui Z, Yu Y, Xu W, Wang F, Lu
J, Wei M, Lu X, Gao X, et al: Oncogenic CUL4A determines the
response to thalidomide treatment in prostate cancer. J Mol Med
(Berl). 90:1121–1132. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Shiyanov P, Nag A and Raychaudhuri P:
Cullin 4A associates with the UV-damaged DNA-binding protein DDB. J
Biol Chem. 274:35309–35312. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Nag A, Bondar T, Shiv S and Raychaudhuri
P: The xeroderma pigmentosum group E gene product DDB2 is a
specific target of cullin 4A in mammalian cells. Mol Cell Biol.
21:6738–6747. 2001. View Article : Google Scholar
|
|
49
|
Kapetanaki MG, Guerrero-Santoro J, Bisi
DC, Hsieh CL, Rapić-Otrin V and Levine AS: The DDB1-CUL4ADDB2
ubiquitin ligase is deficient in xeroderma pigmentosum group E and
targets histone H2A at UV-damaged DNA sites. Proc Natl Acad Sci
USA. 103:2588–2593. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Shinomiya T, Mori T, Ariyama Y, Sakabe T,
Fukuda Y, Murakami Y, Nakamura Y and Inazawa J: Comparative genomic
hybridization of squamous cell carcinoma of the esophagus: The
possible involvement of the DP1 gene in the 13q34 amplicon. Genes
Chromosomes Cancer. 24:337–344. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Dohna M, Reincke M, Mincheva A, Allolio B,
Solinas-Toldo S and Lichter P: Adrenocortical carcinoma is
characterized by a high frequency of chromosomal gains and
high-level amplifications. Genes Chromosomes Cancer. 28:145–152.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Michiels EM, Weiss MM, Hoovers JM, Baak
JP, Voûte PA, Baas F and Hermsen MA: Genetic alterations in
childhood medulloblastoma analyzed by comparative genomic
hybridization. J Pediatr Hematol Oncol. 24:205–210. 2002.
View Article : Google Scholar
|
|
53
|
Englinger B, Mair M, Miklos W, Pirker C,
Mohr T, van Schoonhoven S, Lötsch D, Körner W, Ferk F, Knasmüller
S, et al: Loss of CUL4A expression is underlying cisplatin
hypersensitivity in colorectal carcinoma cells with acquired
trabectedin resistance. Br J Cancer. 116:489–500. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ngan ES: Heterogeneity of neuroblastoma.
Oncoscience. 2:837–838. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Louis CU and Shohet JM: Neuroblastoma:
Molecular pathogenesis and therapy. Annu Rev Med. 66:49–63. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Nader JH, Bourgeois F, Bagatell R, Moreno
L, Pearson ADJ and DuBois SG: Systematic review of clinical drug
development activities for neuroblastoma from 2011 to 2020. Pediatr
Blood Cancer. 70:e301062023. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Bedrnicek J, Vicha A, Jarosova M,
Holzerova M, Cinatl J, Michaelis M, Cinatl J and Eckschlager T:
Characterization of drug-resistant neuroblastoma cell lines by
comparative genomic hybridization. Neoplasma. 52:415–419. 2005.
|
|
58
|
Procházka P, Libra A, Zemanová Z,
Hřebačková J, Poljaková J, Hraběta J, Bunček M, Stiborová M and
Eckschlager T: Mechanisms of ellipticine-mediated resistance in
UKF-NB-4 neuroblastoma cells. Cancer Sci. 103:334–341. 2012.
View Article : Google Scholar
|
|
59
|
Bachetti T, Di Paolo D, Di Lascio S,
Mirisola V, Brignole C, Bellotti M, Caffa I, Ferraris C, Fiore M,
Fornasari D, et al: PHOX2B-mediated regulation of ALK expression:
In vitro identification of a functional relationship between two
genes involved in neuroblastoma. PLoS One. 5:e131082010. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Pfaffl MW, Horgan GW and Dempfle L:
Relative expression software tool (REST) for group-wise comparison
and statistical analysis of relative expression results in
real-time PCR. Nucleic Acids Res. 30:e362002. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kocak H, Ackermann S, Hero B, Kahlert Y,
Oberthuer A, Juraeva D, Roels F, Theissen J, Westermann F, Deubzer
H, et al: Hox-C9 activates the intrinsic pathway of apoptosis and
is associated with spontaneous regression in neuroblastoma. Cell
Death Dis. 4:e5862013. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Su Z, Fang H, Hong H, Shi L, Zhang W,
Zhang W, Zhang Y, Dong Z, Lancashire LJ, Bessarabova M, et al: An
investigation of biomarkers derived from legacy microarray data for
their utility in the RNA-seq era. Genome Biol. 15:5232014.
View Article : Google Scholar
|
|
63
|
Oberthuer A, Berthold F, Warnat P, Hero B,
Kahlert Y, Spitz R, Ernestus K, König R, Haas S, Eils R, et al:
Customized oligonucleotide microarray gene expression-based
classification of neuroblastoma patients outperforms current
clinical risk stratification. J Clin Oncol. 24:5070–5078. 2006.
View Article : Google Scholar
|
|
64
|
Wysocka J, Swigut T, Xiao H, Milne TA,
Kwon SY, Landry J, Kauer M, Tackett AJ, Chait BT, Badenhorst P, et
al: A PHD finger of NURF couples histone H3 lysine 4 trimethylation
with chromatin remodelling. Nature. 442:86–90. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Li S, Shen L and Chen KN: Association
between H3K4 methylation and cancer prognosis: A meta-analysis.
Thoracic Cancer. 9:794–799. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Tumber A, Nuzzi A, Hookway ES, Hatch SB,
Velupillai S, Johansson C, Kawamura A, Savitsky P, Yapp C,
Szykowska A, et al: Potent and selective KDM5 inhibitor stops
cellular demethylation of H3K4me3 at transcription start sites and
proliferation of MM1S myeloma cells. Cell Chem Biol. 24:371–380.
2017. View Article : Google Scholar
|
|
67
|
Brodeur GM, Pritchard J, Berthold F,
Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE,
Favrot M, Hedborg F, et al: Revisions of the international criteria
for neuroblastoma diagnosis, staging and response to treatment. J
Clin Oncol. 11:1466–1477. 1993. View Article : Google Scholar
|
|
68
|
Cheung NK, Kushner BH, LaQuaglia M, Kramer
K, Gollamudi S, Heller G, Gerald W, Yeh S, Finn R, Larson SM, et
al: N7: A novel multi-modality therapy of high-risk neuroblastoma
in children diagnosed over 1 year of age. Med Pediatr Oncol.
36:227–230. 2001. View Article : Google Scholar
|
|
69
|
Haupt S, Caramia F, Klein SL, Rubin JB and
Haupt Y: Sex disparities matter in cancer development and therapy.
Nat Rev Cancer. 21:393–407. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Hollows R, Wei W, Cazier JB, Mehanna H,
Parry G, Halford G and Murray P: Association between loss of Y
chromosome and poor prognosis in male head and neck squamous cell
carcinoma. Head Neck. 41:993–1006. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Huang RS, Kistner EO, Bleibel WK, Shukla
SJ and Dolan ME: Effect of population and gender on
chemotherapeutic agent-induced cytotoxicity. Mol Cancer Ther.
6:31–36. 2007. View Article : Google Scholar : PubMed/NCBI
|
